2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework

The Amyloid, Tau, and Neurodegeneration (A/T/N) Classification Applied to a Clinical Research Cohort with Long-Term Follow-Up

(2020) Gøril Rolfseng Grøntvedt et al.   JOURNAL OF ALZHEIMERS DISEASE

Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic Revisited

(2020) Leo Boelaarts et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease

(2020) Emma E. Wolters et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

CSF p-tau/Aβ42 ratio and brain FDG-PET may reliably detect MCI “imminent” converters to AD

(2020) Roberto Santangelo et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease

(2020) Shorena Janelidze et al.   Nature Communications

Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification

(2020) Nicolas R. Barthélemy et al.   Alzheimers Research & Therapy

Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes

(2020) Adam S. Fleisher et al.   JAMA Neurology

Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders

(2020) Antoine Leuzy et al.   JAMA Neurology

Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease

(2020) Niklas Mattsson-Carlgren et al.   Science Advances

First amyloid β1‐42 certified reference material for re‐calibrating commercial immunoassays

(2020) Sébastien Boulo et al.   Alzheimers & Dementia

Determining Amyloid-β positivity using [18F]AZD4694 PET imaging

(2020) Joseph Therriault et al.   JOURNAL OF NUCLEAR MEDICINE

Sex differences in CSF biomarkers vary by Alzheimer’s disease stage and APOE ε4 genotype

(2020) Rosha Babapour Mofrad et al.   NEUROLOGY

Sex-dependent effect of APOE on Alzheimer's disease and other age-related neurodegenerative disorders

(2020) Julia Gamache et al.   Disease Models & Mechanisms

Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer’s disease

(2019) Antoine Leuzy et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Tau PET imaging in neurodegenerative tauopathies—still a challenge

(2019) Antoine Leuzy et al.   MOLECULAR PSYCHIATRY

Associations between baseline amyloid, sex and APOE on subsequent tau accumulation in cerebrospinal fluid

(2019) Rachel F. Buckley et al.   NEUROBIOLOGY OF AGING

Clinical impact of [18F]flutemetamol PET among memory clinic patients with an unclear diagnosis

(2019) Antoine Leuzy et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study

(2019) Alberto Lleó et al.   Alzheimers & Dementia

Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid

(2019) Valeria Lifke et al.   CLINICAL BIOCHEMISTRY

Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia

(2019) Gil D. Rabinovici et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Comparative evaluation of two immunoassays for cerebrospinal fluid β-Amyloid1–42 measurement

(2019) Chiara Zecca et al.   CLINICA CHIMICA ACTA

Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid Aβ42 and T-Tau assays for Alzheimer’s disease diagnosis

(2019) Jean-Louis Bayart et al.   JOURNAL OF NEUROLOGY

Towards a unified protocol for handling of CSF before β-amyloid measurements

(2019) Shorena Janelidze et al.   Alzheimers Research & Therapy

What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France

(2019) Emmanuel Cognat et al.   BMJ Open

Amyloid-β PET—Correlation with cerebrospinal fluid biomarkers and prediction of Alzheimer´s disease diagnosis in a memory clinic

(2019) Ebba Gløersen Müller et al.   PLoS One

Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study

(2019) Ingrid S van Maurik et al.   LANCET NEUROLOGY

Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer’s disease

(2019) Maria João Leitão et al.   Alzheimers Research & Therapy

Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology

(2019) Kaj Blennow et al.   BRAIN

CSF cutoffs for MCI due to AD depend on APOEε4 carrier status

(2019) Moira Marizzoni et al.   NEUROBIOLOGY OF AGING

Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays

(2019) Kaj Blennow et al.   Scientific Reports

Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid

(2019) Anna Rosenberg et al.   Alzheimers Research & Therapy

Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging

(2018) Suzanne E. Schindler et al.   Alzheimers & Dementia

Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease

(2018) Courtney L. Sutphen et al.   Alzheimers & Dementia

The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review

(2018) Oskar Hansson et al.   Alzheimers & Dementia

CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts

(2018) Oskar Hansson et al.   Alzheimers & Dementia

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

Commutability of the certified reference materials for the standardization of β-amyloid 1-42 assay in human cerebrospinal fluid: lessons for tau and β-amyloid 1-40 measurements

(2018) Ulf Andreasson et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

The Past and the Future of Alzheimer’s Disease Fluid Biomarkers

(2018) Kaj Blennow et al.   JOURNAL OF ALZHEIMERS DISEASE

A ‘Framingham-like’ Algorithm for Predicting 4-Year Risk of Progression to Amnestic Mild Cognitive Impairment or Alzheimer’s Disease Using Multidomain Information

(2018) Kyle Steenland et al.   JOURNAL OF ALZHEIMERS DISEASE

Reproducibility of Alzheimer’s Disease Cerebrospinal Fluid-Biomarker Measurements under Clinical Routine Conditions

(2018) Jonathan Vogelgsang et al.   JOURNAL OF ALZHEIMERS DISEASE

Effects of APOE ε4 on neuroimaging, cerebrospinal fluid biomarkers and cognition in prodromal Alzheimer’s disease

(2018) Niklas Mattsson et al.   NEUROBIOLOGY OF AGING

Comparing18F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease

(2018) Niklas Mattsson et al.   NEUROLOGY

Tau Kinetics in Neurons and the Human Central Nervous System

(2018) Chihiro Sato et al.   NEURON

Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau

(2018) Timothy J. Hohman et al.   JAMA Neurology

FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort

(2018) Silvia Paola Caminiti et al.   NeuroImage-Clinical

Performance of Aβ1-40, Aβ1-42, Total Tau, and Phosphorylated Tau as Predictors of Dementia in a Cohort of Patients with Mild Cognitive Impairment

(2018) Lucilla Parnetti et al.   JOURNAL OF ALZHEIMERS DISEASE

Longitudinal Cerebrospinal Fluid Biomarkers over Four Years in Mild Cognitive Impairment

(2018) Niklas Mattsson et al.   JOURNAL OF ALZHEIMERS DISEASE

Validation of the AD-CSF-Index in Autopsy-Confirmed Alzheimer's Disease Patients and Healthy Controls

(2018) Hanne Struyfs et al.   JOURNAL OF ALZHEIMERS DISEASE

Cost-Effectiveness of the Use of Biomarkers in Cerebrospinal Fluid for Alzheimer's Disease

(2018) Cristina Valcárcel-Nazco et al.   JOURNAL OF ALZHEIMERS DISEASE

Amyloid-β 42/40 Cerebrospinal Fluid Concentration Ratio in the Diagnostics of Alzheimer's Disease: Validation of Two Novel Assays

(2018) Piotr Lewczuk et al.   JOURNAL OF ALZHEIMERS DISEASE

Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A Multicenter Study in Spain

(2018) Daniel Alcolea et al.   JOURNAL OF ALZHEIMERS DISEASE

Biomarkers for Alzheimer's disease: current status and prospects for the future

(2018) K. Blennow et al.   JOURNAL OF INTERNAL MEDICINE

Interlaboratory proficiency processing scheme in CSF aliquoting: implementation and assessment based on biomarkers of Alzheimer’s disease

(2018) Piotr Lewczuk et al.   Alzheimers Research & Therapy

Automation vs. Experience: Measuring Alzheimer’s Beta-Amyloid 1–42 Peptide in the CSF

(2018) Alexander L. Kollhoff et al.   Frontiers in Aging Neuroscience

Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease

(2018) Claudia Cicognola et al.   ACTA NEUROPATHOLOGICA

Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease

(2018) Leslie M. Shaw et al.   Alzheimers & Dementia

Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network

(2018) Aurélie Bussy et al.   NEUROBIOLOGY OF AGING

Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia

(2017) Ignacio Álvarez et al.   JOURNAL OF ALZHEIMERS DISEASE

Prediction of Alzheimer’s Dementia in Patients with Amnestic Mild Cognitive Impairment in Clinical Routine: Incremental Value of Biomarkers of Neurodegeneration and Brain Amyloidosis Added Stepwise to Cognitive Status

(2017) Catharina Lange et al.   JOURNAL OF ALZHEIMERS DISEASE

Cost-Utility of Using Alzheimer’s Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia

(2017) Ron L.H. Handels et al.   JOURNAL OF ALZHEIMERS DISEASE

Mass-Spectrometry-Based Method To Quantify in Parallel Tau and Amyloid β 1–42 in CSF for the Diagnosis of Alzheimer’s Disease

(2017) Gwënaël Pottiez et al.   JOURNAL OF PROTEOME RESEARCH

Diurnal oscillation of CSF Aβ and other AD biomarkers

(2017) Brendan P. Lucey et al.   Molecular Neurodegeneration

The biomarker-based diagnosis of Alzheimer's disease. 2—lessons from oncology

(2017) Marina Boccardi et al.   NEUROBIOLOGY OF AGING

Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework

(2017) Valentina Garibotto et al.   NEUROBIOLOGY OF AGING

Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: an Italian intersocietal roadmap

(2017) Giovanni B. Frisoni et al.   NEUROBIOLOGY OF AGING

Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework

(2017) Konstantinos Chiotis et al.   NEUROBIOLOGY OF AGING

Clinical validity of delayed recall tests as a gateway biomarker for Alzheimer's disease in the context of a structured 5-phase development framework

(2017) Chiara Cerami et al.   NEUROBIOLOGY OF AGING

Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework

(2017) Mara ten Kate et al.   NEUROBIOLOGY OF AGING

Clinical validity of presynaptic dopaminergic imaging with  123 I-ioflupane and noradrenergic imaging with 123 I-MIBG in the differential diagnosis between Alzheimer's disease and dementia with Lewy bodies in the context of a structured 5-phase development framework

(2017) Ida Sonni et al.   NEUROBIOLOGY OF AGING

Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework

(2017) Niklas Mattsson et al.   NEUROBIOLOGY OF AGING

Cerebrospinal fluid biomarkers for Alzheimer's and vascular disease vary by age, gender, and APOE genotype in cognitively normal adults

(2017) Ge Li et al.   Alzheimers Research & Therapy

Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population

(2017) Daniela Bertens et al.   Alzheimers Research & Therapy

Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimer’s disease

(2017) Spencer A. W. Lee et al.   Alzheimers Research & Therapy

Fear and Uncertainty Do Not Influence Reported Willingness to Undergo Lumbar Punctures in a U.S. Multi-Cultural Cohort

(2017) Dobromira Z. Tsvetkova et al.   Frontiers in Aging Neuroscience

Factors that influence the levels of cerebrospinal fluid biomarkers in memory clinic patients

(2017) Anne-Brita Knapskog et al.   BMC Geriatrics

Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer’s Biomarkers in Daily Practice (ABIDE) Project

(2017) Ingrid S. van Maurik et al.   JAMA Neurology

CSF Biomarkers in Alzheimer's Disease and Controls: Associations with APOE Genotype are Modified by Age

(2017) Maartje I. Kester et al.   JOURNAL OF ALZHEIMERS DISEASE

Evaluation of CSF Biomarkers as Predictors of Alzheimer's Disease: A Clinical Follow-Up Study of 4.7 Years

(2017) Joakim Hertze et al.   JOURNAL OF ALZHEIMERS DISEASE

Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study

(2016) Flora H. Duits et al.   Alzheimers & Dementia

Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1–42) in human cerebrospinal fluid

(2016) Tobias Bittner et al.   Alzheimers & Dementia

TDP-43 stage, mixed pathologies, and clinical Alzheimer’s-type dementia

(2016) Bryan D. James et al.   BRAIN

Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography

(2016) Sebastian Palmqvist et al.   BRAIN

The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging

(2016) Brian A. Gordon et al.   BRAIN

Sex differences in the association between AD biomarkers and cognitive decline

(2016) Mary Ellen I. Koran et al.   Brain Imaging and Behavior

Performance Evaluation of an Automated ELISA System for Alzheimer’s Disease Detection in Clinical Routine

(2016) Davide Chiasserini et al.   JOURNAL OF ALZHEIMERS DISEASE

Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid Aβ42 and the Ratios of Aβ Isoforms Using Low Protein Binding Tubes

(2016) Hugo Marcel Johan Vanderstichele et al.   JOURNAL OF ALZHEIMERS DISEASE

Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer’s Disease Dementia

(2016) Salvatore Mazzeo et al.   JOURNAL OF ALZHEIMERS DISEASE

Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly

(2016) Jasmeer P. Chhatwal et al.   NEUROLOGY

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease

(2016) Matthew R. Brier et al.   Science Translational Medicine

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease

(2016) Shorena Janelidze et al.   Annals of Clinical and Translational Neurology

Cerebral white matter lesions – associations with Aβ isoforms and amyloid PET

(2016) Danielle van Westen et al.   Scientific Reports

Plasma β-amyloid in Alzheimer’s disease and vascular disease

(2016) Shorena Janelidze et al.   Scientific Reports

Benchmarking biomarker-based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem

(2015) Christoffer Rosén et al.   Alzheimers & Dementia

Early cost-utility analysis of general and cerebrospinal fluid-specific Alzheimer's disease biomarkers for hypothetical disease-modifying treatment decision in mild cognitive impairment

(2015) Ron L.H. Handels et al.   Alzheimers & Dementia

The transitional association between β-amyloid pathology and regional brain atrophy

(2015) Philip S. Insel et al.   Alzheimers & Dementia

Diagnostic impact of CSF biomarkers for Alzheimer's disease in a tertiary memory clinic

(2015) Flora H. Duits et al.   Alzheimers & Dementia

CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study

(2015) Michael Ewers et al.   Alzheimers & Dementia

The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey

(2015) Martina Bocchetta et al.   Alzheimers & Dementia

Trends in Lumbar Puncture Over 2 Decades: A Dramatic Shift to Radiology

(2015) Hannes Kroll et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Alzheimer’s disease cerebrospinal fluid biomarker in cognitively normal subjects

(2015) Jon B. Toledo et al.   BRAIN

Cerebrospinal fluid tau and amyloid-β1-42in patients with dementia

(2015) Tobias Skillbäck et al.   BRAIN

Attitudes to Alzheimer's disease testing of Australian general practice patients: a cross-sectional questionnaire-based study

(2015) Parker Magin et al.   INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY

Use of amyloid-PET to determine cutpoints for CSF markers

(2015) Marissa D. Zwan et al.   NEUROLOGY

Lumbar puncture refusal in sub-Saharan Africa: A call for further understanding and intervention

(2015) K. T. Thakur et al.   NEUROLOGY

Amyloid biomarkers in Alzheimer's disease

(2015) Kaj Blennow et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age

(2015) Courtney L. Sutphen et al.   JAMA Neurology

The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

(2014) José Luis Molinuevo et al.   Alzheimers & Dementia

The cerebrospinal fluid “Alzheimer profile”: Easily said, but what does it mean?

(2014) Flora H. Duits et al.   Alzheimers & Dementia

Sex modifies theAPOE-related risk of developing Alzheimer disease

(2014) Andre Altmann et al.   ANNALS OF NEUROLOGY

Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease

(2014) Niklas Mattsson et al.   BRAIN

Diagnosis of Prodromal Alzheimer's Disease: Do You Really Want to Know?

(2014) Serge Gauthier et al.   CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

Mass Spectrometry-Based Candidate Reference Measurement Procedure for Quantification of Amyloid-  in Cerebrospinal Fluid

(2014) A. Leinenbach et al.   CLINICAL CHEMISTRY

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

(2014) Bruno Dubois et al.   LANCET NEUROLOGY

Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer's Disease

(2014) A. M. Fagan et al.   Science Translational Medicine

The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI)

(2014) Shannon Risacher   Frontiers in Aging Neuroscience

Routine lumbar puncture for the early diagnosis of Alzheimer's disease. Is it safe?

(2014) Manuel Menéndez-González   Frontiers in Aging Neuroscience

Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β-Amyloid 42

(2014) Sebastian Palmqvist et al.   JAMA Neurology

Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease

(2014) Ronald Lautner et al.   JAMA Psychiatry

Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI

(2013) Jon B. Toledo et al.   ACTA NEUROPATHOLOGICA

Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series

(2013) Gabor G. Kovacs et al.   ACTA NEUROPATHOLOGICA

Cerebral amyloid PET imaging in Alzheimer’s disease

(2013) Clifford R. Jack et al.   ACTA NEUROPATHOLOGICA

CSF biomarker variability in the Alzheimer's Association quality control program

(2013) Niklas Mattsson et al.   Alzheimers & Dementia

Higher Rates of Decline for Women andApolipoprotein Eε4 Carriers

(2013) D. Holland et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Costs of diagnosing dementia: results from SveDem, the Swedish Dementia Registry

(2013) Anders Wimo et al.   INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

(2013) Victor L Villemagne et al.   LANCET NEUROLOGY

BrainAGE in Mild Cognitive Impaired Patients: Predicting the Conversion to Alzheimer’s Disease

(2013) Christian Gaser et al.   PLoS One

Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer’s Disease

(2013) Jere E. Meredith Jr. et al.   PLoS One

Diagnosis and management of Alzheimer's disease: Past, present and future ethical issues

(2013) S. Gauthier et al.   PROGRESS IN NEUROBIOLOGY

Cerebrospinal Fluid Levels ofβ-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia

(2012) Peder Buchhave   ARCHIVES OF GENERAL PSYCHIATRY

Determining cut-points for Alzheimer’s disease biomarkers: statistical issues, methods and challenges

(2012) Jonathan W Bartlett et al.   Biomarkers in Medicine

Recommendations to standardize preanalytical confounding factors in Alzheimer’s and Parkinson’s disease cerebrospinal fluid biomarkers: an update

(2012) Marta del Campo et al.   Biomarkers in Medicine

Dementia Diagnosis Differs in Men and Women and Depends on Age and Dementia Severity: Data from SveDem, the Swedish Dementia Quality Registry

(2012) Dorota Religa et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010

(2012) Thomas G. Beach et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI

(2012) Stephanie Vos et al.   NEUROBIOLOGY OF AGING

Age and diagnostic performance of Alzheimer disease CSF biomarkers

(2012) N. Mattsson et al.   NEUROLOGY

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease

(2012) Randall J. Bateman et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers

(2011) Niklas Mattsson et al.   Alzheimers & Dementia

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Marilyn S. Albert et al.   Alzheimers & Dementia

Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

(2011) Hugo Vanderstichele et al.   Alzheimers & Dementia

Evidence for Ordering of Alzheimer Disease Biomarkers

(2011) Clifford R. Jack   ARCHIVES OF NEUROLOGY

GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables

(2011) Gordon Guyatt et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)

(2011) Gordon H. Guyatt et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Multimodal classification of Alzheimer's disease and mild cognitive impairment

(2011) Daoqiang Zhang et al.   NEUROIMAGE

Combining MR Imaging, Positron-Emission Tomography, and CSF Biomarkers in the Diagnosis and Prognosis of Alzheimer Disease

(2010) K.B. Walhovd et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People

(2010) Geert De Meyer   ARCHIVES OF NEUROLOGY

Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic

(2010) Maartje I. Kester et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging

(2010) Christopher C. Rowe et al.   NEUROBIOLOGY OF AGING

Comparing predictors of conversion and decline in mild cognitive impairment

(2010) S. M. Landau et al.   NEUROLOGY

Decreased Clearance of CNS  -Amyloid in Alzheimer's Disease

(2010) K. G. Mawuenyega et al.   SCIENCE

Effect of APOE on biomarkers of amyloid load and neuronal pathology in AD

(2009) Prashanthi Vemuri et al.   ANNALS OF NEUROLOGY

The neuropathology of probable Alzheimer disease and mild cognitive impairment

(2009) Julie A. Schneider et al.   ANNALS OF NEUROLOGY

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

(2009) Leslie M. Shaw et al.   ANNALS OF NEUROLOGY

APOEpredicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging

(2009) John C. Morris et al.   ANNALS OF NEUROLOGY

Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe

(2009) J. Hort et al.   EUROPEAN JOURNAL OF NEUROLOGY

Clinical and cost effectiveness of services for early diagnosis and intervention in dementia

(2009) Sube Banerjee et al.   INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study

(2009) Pieter Jelle Visser et al.   LANCET NEUROLOGY

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

(2009) Clifford R Jack et al.   LANCET NEUROLOGY

MRI and CSF biomarkers in normal, MCI, and AD subjects: Predicting future clinical change

(2009) P. Vemuri et al.   NEUROLOGY

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment

(2008) Clifford R. Jack et al.   BRAIN

Alzheimer disease with cerebrovascular disease and vascular dementia: clinical features and course compared with Alzheimer disease

(2008) A Bruandet et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Characterization of Tau in Cerebrospinal Fluid Using Mass Spectrometry

(2008) Erik Portelius et al.   JOURNAL OF PROTEOME RESEARCH